The pursuit for biotherapeutic proteins in basic research, clinical diagnostics and therapy continues at an exponential pace. Consequently, the demands for efficient expression and production of these valuable biomolecules face challenges to improve quantity and quality while minimising time and cost. Thus, an increasing variety of recombinant production platforms, called “cell factories,” are being developed. Unfortunately, there is no universal production system which can guarantee high yields, since each protein can vary in terms of expression and production.

Preliminary Agenda


Humanization and Simultaneous Optimization of Monoclonal and Bispecific Antibody

Christine X. Koo, PhD, Senior Scientist I, Lead optimization, Chugai Pharmabody Research

Rapid Selection of CHO Clones Secreting Chimeric Antibody-Antigen Fusion Constructs Based on 2A-Peptide Cleavage and GFP

Bert Devriendt, PhD, Postdoctoral Scientist, Department of Virology, Parasitology, Immunology, Physiology, Ghent University

High Throughput Antibody Production and Purification: Day to Day Challenges and How to Overcome Them

Peter Schmidt, PhD, Director, Recombinant Technologies Research, CSL Behring

High Density (HD) Expression Platform: The One-Stop-Solution for Recombinant Antibody Production

Bowu Luan, PhD, Product Manager, GenScript USA, Inc.


The Use of Design of Experiments in Recombinant Protein Production; Concepts and Case Studies

Barry Ryan, BSc (Hons), PGDip, MSc, MA, PhD, Lecturer, Food Science and Environmental Health, College of Health and Science, Technological University Dublin

Tuning Recombinant Protein Expression to Match Secretion Capacity

Neil Dixon, PhD, David Phillips Research Fellow, Manchester Institute of Biotechnology, University of Manchester

A Recovery Toolbox: Molecular Approaches to Enhance Protein Folding and Soluble Yield from Bacterial Expression Systems

Christopher H. Gray, PhD, Team Leader (Structural Biology), Drug Discovery Program, CRUK Beatson Institute

Improved Production of Recombinant Proteins from Insect Cells through Promoter, Virus, and Strain Enhancements

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research


Production of Hard-to-Produce Proteins Using Genome Engineered CHO Cells

Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

High-Yield Production of "Difficult-to-Express" Proteins in an Improved Cell-Free System

Takanori Kigawa, DSci, Team Leader, Center for Biosystems Dynamics Research, RIKEN


Choosing Right between Transient and Stable Protein Expression Systems while Supporting Fast-Paced Biologics Discovery

Kinjal Mehta, PhD, Principal Scientist, Protein Sciences, Jounce Therapeutics

Scaling Up and Scaling Out: Pushing the Boundaries of Transient Protein Production

Ian Wilkinson, PhD, CSO, Absolute Antibody Ltd.

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese